CGOC Announces Investment in US Medical Cannabis Leader Vireo Health

Published: August 14, 2018

CGOC Announces Investment in US Medical Cannabis Leader Vireo Health

Cannabis Growth Opportunity Corporation announced the company has made an investment in Vireo Health Inc., a physician-led company with a mission to safely alleviate pain with cannabis and dedicated to providing best-in-class cannabis-based medications and compassionate care. The deal reflects CGOC’s commitment to investing in organizations poised to drive long-term growth for the company’s investors.

A North American leader in the pain vertical within medical marijuana, Vireo cultivates cannabis in environmentally friendly greenhouses and manufacturers pharmaceutical-grade cannabis extracts in their state-of-the-art labs. Its robust IP portfolio includes a mix of medical and general cannabis applications including harm reduction additive for tobacco products, its FREDOM opioid reduction protocol and a custom extract dispenser.

“Our investment in Vireo is a great example of our team of cannabis industry experts leveraging our early mover advantage to invest in companies with a proven track-record of launching new operations in an expedited and efficient manner,” said Jamie Blundell, President and COO of CGOC. “Their offering is distinct, and they are poised to change the landscape for how cannabis will be utilized from a medical perspective. They’re showing real revenue today and we’re very excited about their direction and the opportunity our funding has to drive long-term value for our investors.”

CGOC is investing $1,507,500 USD for 33,500 shares in Vireo. The company plans to use the funding to expand into new markets.

Currently available in Minnesota, New York and Pennsylvania, Vireo products are sold through licensed retail dispensaries, direct to consumer as well as wholesale. The company has license applications pending in Maryland and Ohio with plans to expand into other U.S. states in the near future.

Members of Vireo’s leadership team are involved in several research and clinical studies including a research study with the National Institute of Health’s exploring the use of cannabis as an alternative to opioids.

“This investment will allow Vireo to continue to fulfill its compassionate mission of helping patients safely alleviate pain with cannabis and execute on our aggressive growth plans” said, Kyle Kingsley, M.D, Vireo’s Chairman & Chief Executive Officer. “We’re pleased that the CGOC team sees the potential in our offerings and ability to deliver growth for their investors.”

Recent News

View All News Items

Latest Article

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

At any step in the cannabis supply chain, your labeling system should allow for full control and traceability, from seed to sale. Implementing lean principles and labeling best practices across the cannabis supply chain can help you streamline your seed-to-sale labeling process and help you gain control.

Click below to read the full blog and learn how to reduce waste, cut costs, and gain efficiency with cannabis labeling: https://bit.ly/2KwZ5IQ

Read Article